EXEL inciting excitement
McBio, you may be missing the train. EXEL is up another 7% today. The reason appears to be comments made by CEO today at the BioCEO conference. Adam Feuerstein reported this regarding XL-184, which is becoming known as cabozantinib or "cabo":
Thursday -- updated data will be released at 4 pm. aniticpate 100 evaluable patients, with approx 50 patients with mets on bone scan. expect duration follow up of approx 4 months.
the abstract comes out tomorrow but those data are preliminary. exel will have more data on thursday.......
..readout of top line data from ph 3 data in medullary thyroid cancer expected in 2h 2011.
There will be an investor event on Thursday, also. The way this is being spun, it is hard to believe the new data on cabo could be negative.
The spin from the company turned toward the incredulous when he apparently said accelerated approval by FDA was possible in 2011.
Urche
Market Data 
Markets 
AI
